Description

Naltrexone USP/EP

Naltrexone USP/EP is a high-purity opioid receptor antagonist used in oral and injectable pharmaceutical formulations for the treatment of alcohol dependence and opioid use disorder.

• It is a pharmaceutical-grade API with a strong safety and efficacy profile
• It inhibits opioid receptor activation and reduces alcohol craving
• It is s suitable for oral tablets and extended-release injectable formulations
• It is manufactured under cGMP
• It is supplied with full regulatory documentation

Naltrexone plays a critical role in relapse prevention protocols, helping reduce the rewarding effects of opioids and alcohol by acting as a competitive antagonist at μ-opioid receptors. Its pharmacokinetic and pharmacodynamic properties make it a versatile choice for short- and long-term treatment settings.

Used in a variety of delivery forms including tablets, injections, and implantable systems, Naltrexone supports therapy compliance in detoxification programs, maintenance treatment, and alcohol dependence management. It is also commonly studied in combination protocols and behavioral support regimens.

CarboMer supplies high-purity Naltrexone in bulk to formulators and pharmaceutical manufacturers. Each batch undergoes strict analytical testing for potency, identity, and purity to meet regulatory standards.

This API is available in packaging configurations suitable for R&D, pilot, and commercial-scale production. Packaging options, MOQ, and lead time are flexible to meet supply chain needs.

CarboMer provides regulatory assistance and formulation support, including access to regulatory documentation accelerate product development and approval timelines.

As with all CarboMer APIs, Naltrexone is backed by end-to-end support to streamline compliance, optimize performance, and ensure success in development through commercialization.